Humanized Alzheimer's Disease (AD) Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Myasthenia Gravis (MG) ModelsAutoimmune Nephropathy modelsAcute Lung Injury ModelsIdiopathic Pulmonary Fibrosis ModelsSjögren’ s Syndrome ModelsSystemic Lupus Erythematosus (SLE) ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsMASH ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Autosomal Dominant Polycystic Kidney Disease (ADPKD)Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurological Disease Mouse Models
Alzheimer's Disease (AD) ModelsHumanized Alzheimer's Disease (AD) ModelsParkinson's Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) ModelsDuchenne Muscular Dystrophy (DMD) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by an insidious onset and progressive development. The primary clinical features of the disease include progressive memory impairment, cognitive decline, executive dysfunction, as well as accompanying language disorders, motor function impairment, personality changes, and neuropsychiatric symptoms.

Most existing AD mouse models are constructed by introducing APP gene mutations carried by familial AD patients. However, familial AD patients account for less than 5% of clinical AD cases, with the majority of AD patients having sporadic AD and not carrying familial AD mutations. Therefore, by introducing multiple sporadic AD-related risk genes, such as TREM2 and APOE4, into the FAD4T model, it is possible to better simulate the disease phenotypes of sporadic AD patients.

GemPharmatech has developed three humanized AD models that can be utilized for the screening and safety evaluation of Alzheimer's disease treatments.


Strain No.

Strain Name

Strain Type

Description

T058996

FAD4T-hTREM2

Transgenic

The TREM2 humanized FAD4T-hTREM2 mouse model was constructed based on the FAD4T background, which can be used to evaluate the efficacy of monoclonal antibodies or small molecule drugs.

/

FAD4T-hAPOE3

Transgenic

In Development (Please inquire)

/

FAD4T-hAPOE4

Transgenic

In Development (Please inquire)